John Scott Roth1, Gary J Anthone2, Don J Selzer3, Benjamin K Poulose4, James G Bittner5, William W Hope6, Raymond M Dunn7, Robert G Martindale8, Matthew I Goldblatt9, David B Earle10, John R Romanelli10, Gregory J Mancini11, Jacob A Greenberg12, John G Linn13, Eduardo Parra-Davila14, Bryan J Sandler15, Corey R Deeken16, Guy R Voeller11. 1. Department of Surgery, University of Kentucky Medical Center, 800 Rose Street, #C225, Lexington, KY, 40536, USA. s.roth@uky.edu. 2. Department of Surgery, Methodist Health System, Omaha, NE, USA. 3. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. 4. Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Surgery, Virginia Commonwealth University, Richmond, VA, USA. 6. Department of Surgery, New Hanover Regional Medical Center, Wilmington, NC, USA. 7. Department of Surgery, University of Massachusetts Worcester, Worcester, MA, USA. 8. Department of Surgery, Oregon Health & Science University, Portland, OR, USA. 9. Department of Surgery, The Medical College of Wisconsin, Inc., Milwaukee, WI, USA. 10. Department of Surgery, Baystate Medical Center, Springfield, MA, USA. 11. Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA. 12. Department of Surgery, Board of Regents of the University of Wisconsin System, Madison, WI, USA. 13. Department of Surgery, North Shore University Health System, Evanston, IL, USA. 14. Department of Surgery, Celebration Health, Celebration, FL, USA. 15. Department of Surgery, The Regents of the University of California, San Diego, CA, USA. 16. Covalent Bio, LLC, St. Louis, MO, USA.
Abstract
BACKGROUND: Long-term resorbable mesh represents a promising technology for complex ventral and incisional hernia repair (VIHR). Preclinical studies indicate that poly-4-hydroxybutyrate (P4HB) resorbable mesh supports strength restoration of the abdominal wall. This study evaluated outcomes of high-risk subjects undergoing VIHR with P4HB mesh. METHODS: This was a prospective, multi-institutional study of subjects undergoing retrorectus or onlay VIHR. Inclusion criteria were CDC Class I, defect 10-350 cm2, ≤ 3 prior repairs, and ≥ 1 high-risk criteria (obesity (BMI: 30-40 kg/m2), active smoker, COPD, diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, hypoalbuminemia, advanced age, and renal insufficiency). Physical exam and/or quality of life surveys were performed at regular intervals through 18 months (to date) with longer-term, 36-month follow-up ongoing. RESULTS:One hundred and twenty-one subjects (46M, 75F) with an age of 54.7 ± 12.0 years and BMI of 32.2 ± 4.5 kg/m2 (mean ± SD), underwent VIHR. Comorbidities included the following: obesity (n = 95, 78.5%), hypertension (n = 72, 59.5%), cardiovascular disease (n = 42, 34.7%), diabetes (n = 40, 33.1%), COPD (n = 34, 28.1%), malignancy (n = 30, 24.8%), active smoker (n = 28, 23.1%), immunosuppression (n = 10, 8.3%), chronic corticosteroid use (n = 6, 5.0%), advanced age (n = 6, 5.0%), hypoalbuminemia (n = 3, 2.5%), and renal insufficiency (n = 1, 0.8%). Hernia types included the following: primary ventral (n = 17, 14%), primary incisional (n = 54, 45%), recurrent ventral (n = 15, 12%), and recurrent incisional hernia (n = 35, 29%). Defect and mesh size were 115.7 ± 80.6 and 580.9 ± 216.1 cm2 (mean ± SD), respectively. Repair types included the following: retrorectus (n = 43, 36%), retrorectus with additional myofascial release (n = 45, 37%), onlay (n = 24, 20%), and onlay with additional myofascial release (n = 8, 7%). 95 (79%) subjects completed 18-month follow-up to date. Postoperative wound infection, seroma requiring intervention, and hernia recurrence occurred in 11 (9%), 7 (6%), and 11 (9%) subjects, respectively. CONCLUSIONS: High-risk VIHR with P4HB mesh demonstrated positive outcomes and low incidence of hernia recurrence at 18 months. Longer-term 36-month follow-up is ongoing.
RCT Entities:
BACKGROUND: Long-term resorbable mesh represents a promising technology for complex ventral and incisional hernia repair (VIHR). Preclinical studies indicate that poly-4-hydroxybutyrate (P4HB) resorbable mesh supports strength restoration of the abdominal wall. This study evaluated outcomes of high-risk subjects undergoing VIHR with P4HB mesh. METHODS: This was a prospective, multi-institutional study of subjects undergoing retrorectus or onlay VIHR. Inclusion criteria were CDC Class I, defect 10-350 cm2, ≤ 3 prior repairs, and ≥ 1 high-risk criteria (obesity (BMI: 30-40 kg/m2), active smoker, COPD, diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, hypoalbuminemia, advanced age, and renal insufficiency). Physical exam and/or quality of life surveys were performed at regular intervals through 18 months (to date) with longer-term, 36-month follow-up ongoing. RESULTS: One hundred and twenty-one subjects (46M, 75F) with an age of 54.7 ± 12.0 years and BMI of 32.2 ± 4.5 kg/m2 (mean ± SD), underwent VIHR. Comorbidities included the following: obesity (n = 95, 78.5%), hypertension (n = 72, 59.5%), cardiovascular disease (n = 42, 34.7%), diabetes (n = 40, 33.1%), COPD (n = 34, 28.1%), malignancy (n = 30, 24.8%), active smoker (n = 28, 23.1%), immunosuppression (n = 10, 8.3%), chronic corticosteroid use (n = 6, 5.0%), advanced age (n = 6, 5.0%), hypoalbuminemia (n = 3, 2.5%), and renal insufficiency (n = 1, 0.8%). Hernia types included the following: primary ventral (n = 17, 14%), primary incisional (n = 54, 45%), recurrent ventral (n = 15, 12%), and recurrent incisional hernia (n = 35, 29%). Defect and mesh size were 115.7 ± 80.6 and 580.9 ± 216.1 cm2 (mean ± SD), respectively. Repair types included the following: retrorectus (n = 43, 36%), retrorectus with additional myofascial release (n = 45, 37%), onlay (n = 24, 20%), and onlay with additional myofascial release (n = 8, 7%). 95 (79%) subjects completed 18-month follow-up to date. Postoperative wound infection, seroma requiring intervention, and hernia recurrence occurred in 11 (9%), 7 (6%), and 11 (9%) subjects, respectively. CONCLUSIONS: High-risk VIHR with P4HB mesh demonstrated positive outcomes and low incidence of hernia recurrence at 18 months. Longer-term 36-month follow-up is ongoing.
Authors: Alfredo M Carbonell; Cory N Criss; William S Cobb; Yuri W Novitsky; Michael J Rosen Journal: J Am Coll Surg Date: 2013-09-14 Impact factor: 6.113
Authors: Jacobus W A Burger; Roland W Luijendijk; Wim C J Hop; Jens A Halm; Emiel G G Verdaasdonk; Johannes Jeekel Journal: Ann Surg Date: 2004-10 Impact factor: 12.969
Authors: Judy Jin; Michael J Rosen; Jeffrey Blatnik; Michael F McGee; Christina P Williams; Jeffrey Marks; Jeffrey Ponsky Journal: J Am Coll Surg Date: 2007-09-14 Impact factor: 6.113
Authors: Adam S Levy; Jaime L Bernstein; Ishani D Premaratne; Christine H Rohde; David M Otterburn; Kerry A Morrison; Michael Lieberman; Alfons Pomp; Jason A Spector Journal: Surg Endosc Date: 2020-05-08 Impact factor: 4.584
Authors: A N Christopher; M P Morris; V Patel; J A Mellia; C Fowler; C A Messa; R B Broach; J P Fischer Journal: Hernia Date: 2021-04-27 Impact factor: 4.739
Authors: Salvador Morales-Conde; Frederick Berrevoet; Lars Nannestad Jorgensen; Domenico Marchi; Pablo Ortega-Deballon; Alistair Windsor Journal: World J Surg Date: 2022-10-02 Impact factor: 3.282
Authors: S Morales-Conde; P Hernández-Granados; L Tallón-Aguilar; M Verdaguer-Tremolosa; M López-Cano Journal: Hernia Date: 2022-09-13 Impact factor: 2.920
Authors: Jay F Yu; Hannah E Goldblatt; Katie Alter-Troilo; Emily Hetzel; Matthew I Goldblatt Journal: Surg Endosc Date: 2021-12-02 Impact factor: 3.453